Tissue Regenix Group PLC Notice of cyber security incident (1379B)
January 28 2020 - 5:02AM
UK Regulatory
TIDMTRX
RNS Number : 1379B
Tissue Regenix Group PLC
28 January 2020
This announcement contains inside information
Tissue Regenix Group plc
Notice of cyber security incident
Leeds, 28 January 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or the "Company") the regenerative medical devices
company, today reports that it has been subject to a cyber security
incident which involved unauthorised access to its computer
systems, and those of its third-party IT service provider, in the
United States. The Company took immediate steps to respond and
manage the incident, appointing external specialists, including
forensic cyber security experts to investigate the circumstances
and scope of the incident. These investigations are ongoing.
Tissue Regenix has taken precautionary steps, including taking
affected systems offline. This has restricted access to certain
business operations, including the Company's ability in the
short-term to continue manufacturing in its United States facility,
which has been taken offline whilst the incident is being
investigated. The incident is not believed to have impacted its UK
operations or financial systems.
The Company is engaged with its third-party IT service provider,
the relevant legal authorities and cyber security experts to
rectify the incident as quickly as possible and to minimise any
impact on its operations. The time required to resolve the incident
is currently unknown.
The Company is also working to understand and quantify the
potential financial impact of the incident, including protections
afforded under its business disruption insurance.
A further update will be made in due course.
The person responsible for this announcement is John Samuel,
Executive Chairman.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073
Caitlin Pearson Head of Communications
--------------------------------------------- --------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- --------------------
FTI Consulting Tel: 0203 727 1000
Simon Conway / Victoria Foster Mitchell
/ Mary Whittow
============================================= ====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFIFEALTITFII
(END) Dow Jones Newswires
January 28, 2020 05:02 ET (10:02 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2023 to Aug 2024